reports
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study showed that the ADCETRIS combination reduced patients’ risk of death by 37% compared to placebo in combination with lenalidomide and rituximab (HR 0.63 [95% CI: 0.445-0.891] p=0.0085). The overall survival benefit was consistent across levels of CD30 expression. The ECHEL...
Immunocore presents KIMMTRAK clinical data demonstrating that patients...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafusp (IMC-F106C) in advanced cutaneous melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, U...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Tr...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors KT-253 Phase 1 study ongoing wi...
Molecular Partners Presents Positive Data From Completed Phase 1 Trial...
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024 Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironmentFavorable and manageable safety profile observed at all tested dose levelsWeekly and three-weekly dosing schedules established, supported by pharmacokinetics and pharmacodynamicsData support further clinical evaluation of MP0317 in combination settings ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 01, ...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Pha...
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim dataProlongation of 2.1 months in median overall survival (OS) and 1.9 months in median progression-free survival (PFS) in the CM24+nivolumab+Nal-IRI/5FU/LV regimen vs. standard...
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Pha...
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treat...
Thu Dau Mot Joint Stock Company: 1 director
A director at Thu Dau Mot Joint Stock Company sold 2,000,000 shares at 0.000VND and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
NIO Inc. Provides May 2024 Delivery Update
NIO Inc. Provides May 2024 Delivery Update Company Achieved New Record-High Monthly Deliveries NIO delivered 20,544 vehicles in May 2024, increasing by 233.8% year-over-yearNIO delivered 66,217 vehicles year-to-date in 2024, increasing by 51.0% year-over-year Cumulative deliveries of NIO vehicles reached 515,811 as of May 31, 2024 SHANGHAI, June 01, 2024 (GLOBE NEWSWIRE) -- NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a pioneer and a leading company in the premium smart electric vehicle market, today announced its May 2024 delivery results. NIO delivered 20,544...
Wuxi NCE Power Co Ltd: 10 directors
Ten Directors at Wuxi NCE Power Co Ltd sold 330,400 shares at 42.400CNY. The significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
XPENG Announces Vehicle Delivery Results for May 2024
XPENG Announces Vehicle Delivery Results for May 2024 10,146 vehicles delivered in May 2024, a 35% increase year-over-year GUANGZHOU, China, June 01, 2024 (GLOBE NEWSWIRE) -- XPeng Inc. (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced its vehicle delivery results for May 2024. XPENG delivered 10,146 Smart EVs in May, representing a 35% increase year-over-year and an 8% increase over the prior month. The XPENG X9 notably achieved monthly deliveries of 1,625 units, reaching a cumulative total of 11,4...
Shoppers Stop Limited: 3 directors
Three Directors at Shoppers Stop Limited bought/sold 104,952 shares at between 731.890INR and 735.000INR. The significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's d...
Storskogen Group AB: 1 director
A director at Storskogen Group AB bought 300,000 shares at 7.924SEK and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Brookfield Corporation: 1 director
A director at Brookfield Corporation bought 16,667 shares at 60.320CAD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
First Quantum Minerals Ltd: 1 director
A director at First Quantum Minerals Ltd sold 49,250 shares at 17.970CAD and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ye...
NIIT Learning Systems Ltd: 1 director
A director at NIIT Learning Systems Ltd sold 6,666 shares at 440.537INR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Paramount Resources Ltd: 3 directors
Three Directors at Paramount Resources Ltd sold after exercising options/sold/gave away 55,152 shares at between 0.000CAD and 33.012CAD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionar...
Xometry Inc: 1 director
A director at Xometry Inc bought 20,000 shares at 15.410USD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Appian Corp: 1 director
A director at Appian Corp bought 11,000 shares at 28.000USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Zhejiang Sunriver Culture Tourism Co Ltd: 8 directors
Eight Directors at Zhejiang Sunriver Culture Tourism Co Ltd bought 547,400 shares at between 5.100CNY and 5.174CNY. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the c...
Pebblebrook Hotel Trust: 1 director
A director at Pebblebrook Hotel Trust bought 20,000 shares at 13.643USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.